Gómez García Ana María, López Muñoz Francisco, García-Rico Eduardo
Internal Medicine Unit, Hospital Universitario HM Madrid, 28015 Madrid, Spain.
Facultad HM de Ciencias de la Salud de la Universidad Camilo José Cela, 28692 Madrid, Spain.
Curr Issues Mol Biol. 2024 Jul 23;46(8):7812-7831. doi: 10.3390/cimb46080463.
The intestinal microbiota and the human body are in a permanent interaction. There is a symbiotic relationship in which the microbiota plays a vitally important role in the performance of numerous functions, including digestion, metabolism, the development of lymphoid tissue, defensive functions, and other processes. It is a true metabolic organ essential for life and has potential involvement in various pathological states, including cancer and pathologies other than those of a digestive nature. A growing topic of great interest for its implications is the relationship between the microbiota and cancer. Dysbiosis plays a role in oncogenesis, tumor progression, and even the response to cancer treatment. The effect of the microbiota on tumor development goes beyond a local effect having a systemic effect. Another aspect of great interest regarding the intestinal microbiota is its relationship with drugs, modifying their activity. There is increasing evidence that the microbiota influences the therapeutic activity and side effects of antineoplastic drugs and also modulates the response of several tumors to antineoplastic therapy through immunological circuits. These data suggest the manipulation of the microbiota as a possible adjuvant to improve oncological treatment. Is it possible to manipulate the microbiota for therapeutic purposes?
肠道微生物群与人体处于持续的相互作用中。它们存在一种共生关系,其中微生物群在众多功能的发挥中起着至关重要的作用,这些功能包括消化、代谢、淋巴组织发育、防御功能以及其他生理过程。它是生命所必需的真正的代谢器官,并可能参与各种病理状态,包括癌症以及非消化性的其他病症。因其影响而备受关注的一个日益热门的话题是微生物群与癌症之间的关系。生态失调在肿瘤发生、肿瘤进展乃至癌症治疗反应中都发挥着作用。微生物群对肿瘤发展的影响不仅限于局部效应,还具有全身效应。关于肠道微生物群另一个备受关注的方面是它与药物的关系,即微生物群会改变药物的活性。越来越多的证据表明,微生物群会影响抗肿瘤药物的治疗活性和副作用,还会通过免疫途径调节多种肿瘤对抗肿瘤治疗的反应。这些数据表明,操纵微生物群可能作为一种辅助手段来改善肿瘤治疗。是否有可能出于治疗目的操纵微生物群呢?
Curr Issues Mol Biol. 2024-7-23
Rev Endocr Metab Disord. 2018-12
Rev Neurol (Paris). 2023-11
Sheng Wu Gong Cheng Xue Bao. 2022-6-25
Int J Cancer. 2021-2-18
Int J Cancer. 2018-12-30
Integr Cancer Ther. 2020
Cureus. 2023-10-15
Front Pharmacol. 2023-6-9
Biomed Pharmacother. 2023-5
Semin Cancer Biol. 2021-8